Rocket Pharmaceuticals
RCKT
196 hedge funds and large institutions have $233M invested in Rocket Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 47 reducing their positions, and 80 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 47
41% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $1.22M
12.13% less ownership
Funds ownership: 101.11% → 88.98% (-12%)
17% less funds holding
Funds holding: 236 → 196 (-40)
49% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 80
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
68% less capital invested
Capital invested by funds: $722M → $233M (-$490M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$16M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$11.6M |
| 3 |
NM
Newtyn Management
New York
|
+$10.1M |
| 4 |
Two Sigma Investments
New York
|
+$8.74M |
| 5 |
Millennium Management
New York
|
+$8.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$84.2M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$32.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$16.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.85M |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.93M |
RCKT Hedge Fund Activity: Q2 2025 in Review
196 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2025, worth a combined $233M — down 68% from $722M a quarter earlier.
Sellers outnumbered buyers: 80 funds closed out of RCKT and 41 opened new positions — a net loss of 39 holders — while 47 trimmed existing stakes and 81 added.
The largest buyer was Maverick Capital, adding an estimated $16M. The largest seller was Wellington Management Group, exiting entirely with an estimated $84.2M sold.
- 196 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2025, down from 236 in Q1 2025.
- Funds reported $233M of Rocket Pharmaceuticals stock for Q2 2025, down 68% quarter-over-quarter.
- 41 funds opened new Rocket Pharmaceuticals positions in Q2 2025 and 80 closed out, a net change of -39 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2025 was Maverick Capital, an estimated $16M added.
- The largest Rocket Pharmaceuticals seller in Q2 2025 was Wellington Management Group, an estimated $84.2M sold.
Based on aggregated 13F filings for Q2 2025.